Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Rohtan Apr. 21 at 1:55 AM

$BCTX

0 · Reply

TILResearch Apr. 20 at 10:42 PM

$BCTX I thought the posters seemed like pretty good data. QOL better than chemo plus they are going to treat patients at home. I am not really sure why the stock went down but I don't think this changes anything for me at least. Seems pretty likely this will get approved though unless something better beats it to the punch. It should have improved OS, improved QOL, and improved delivery.

2 · Reply

JediGreen Apr. 20 at 9:16 PM

$BCTX

0 · Reply

JediGreen Apr. 20 at 9:15 PM

$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/

0 · Reply

JediGreen Apr. 20 at 9:14 PM

$BCTX I don’t think people where selling just probably some big short seller. Seen 25k shares Lined up on level 2 to sell right off the bat this morning. We’ll see when the short volume is reported after today. So far I’m seen 90 percent of volume was short volume. Now they are going to talk crap.

0 · Reply

_rags_2_riches_ Apr. 20 at 8:15 PM

$BCTX Oof

0 · Reply

Goodstockday Apr. 20 at 8:00 PM

$BCTX I think some were expecting big data today. That was not a surprise given the phase 3 data is not mature yet. What they got was nothing especially relevant to efficacy. Two of the papers were focused on new approaches to blood tests. I am still thinking if I can pull anything useful from the third study. So, we wait for the data to mature. Yes, waiting is no fun, but there are no shortcuts here.

0 · Reply

Kirubin Apr. 20 at 7:56 PM

$BCTX trash🥶

0 · Reply

SmallCapGrowth Apr. 20 at 6:57 PM

$BCTX: presented positive Phase - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6825388

0 · Reply

BHWinehouse Apr. 20 at 6:36 PM

$BCTX Good day to add some warrants $BCTXL

1 · Reply

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 20 days ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 4 weeks ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

Wed, 18 Mar 2026 07:30:00 -0400 - 4 weeks ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 5 weeks ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 6 weeks ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 2 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 2 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 2 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 2 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 2 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 2 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 3 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 3 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 3 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 3 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 3 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 3 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 3 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 3 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 4 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 4 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 4 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 4 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 5 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 5 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 6 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 6 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 6 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 6 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 6 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 6 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Tue, 21 Oct 2025 07:50:00 -0400 - 6 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Tue, 21 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

2025-10-20T13:31:42.000Z - 6 months ago

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

Mon, 20 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 6 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 8 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 8 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 9 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 9 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 9 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 9 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 10 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 10 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 11 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 11 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 11 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Rohtan Apr. 21 at 1:55 AM

$BCTX

0 · Reply

TILResearch Apr. 20 at 10:42 PM

2 · Reply

JediGreen Apr. 20 at 9:16 PM

$BCTX

0 · Reply

JediGreen Apr. 20 at 9:15 PM

$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/

0 · Reply

JediGreen Apr. 20 at 9:14 PM

0 · Reply

_rags_2_riches_ Apr. 20 at 8:15 PM

$BCTX Oof

0 · Reply

Goodstockday Apr. 20 at 8:00 PM

0 · Reply

Kirubin Apr. 20 at 7:56 PM

$BCTX trash🥶

0 · Reply

SmallCapGrowth Apr. 20 at 6:57 PM

$BCTX: presented positive Phase - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6825388

0 · Reply

BHWinehouse Apr. 20 at 6:36 PM

$BCTX Good day to add some warrants $BCTXL

1 · Reply

ZacksResearch Apr. 20 at 5:04 PM

$BCTX just dropped encouraging Phase 3 cancer data — is this flying under the radar? 👀 BriaCell reported positive quality-of-life trends in its Phase 3 Bria-IMT + CPI study for heavily pretreated metastatic breast cancer patients: 📊 Global health status remained stable through treatment 🧠 Emotional & cognitive function maintained 🛡️ Favorable safety profile with durable tolerability Early signals suggest patients are maintaining quality of life even after prior therapies — a key differentiator in late-stage cancer care. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37837&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37837

0 · Reply

DunkenInvest Apr. 20 at 4:22 PM

$BCTX smack that offering and let it sack to 2$

0 · Reply

SmallCapGrowth Apr. 20 at 4:18 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX: presented positive Phase 3 qualit... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177518115 via @Investors_Hub

0 · Reply

Itsybitsybeanbag Apr. 20 at 4:05 PM

$BCTX must be an offering on the way!

0 · Reply

SmallCapGrowth Apr. 20 at 2:38 PM

BriaCell $BCTX just presented game-changing Phase 2 biomarker data! 🔬 They've identified new ways to predict immune checkpoint inhibitor response using novel biomarkers in metastatic breast cancer. https://bit.ly/3QyldE6 #BCTX #Microcap #PennyStocks #BioTechNews

0 · Reply

SmallCapGrowth Apr. 20 at 2:07 PM

BB's Stock Haven : Cancer Stock News: $BCTX Presents Positi... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177518343 via @Investors_Hub

0 · Reply

Kirubin Apr. 20 at 1:56 PM

$BCTX 🤦🏽‍♂️🥶🤭

0 · Reply

Goodluckeverday Apr. 20 at 1:53 PM

$BCTX er...but why drop.....???

1 · Reply

SmallCapGrowth Apr. 20 at 1:42 PM

Cancer Stock News: $BCTX Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting –“patients with metastatic breast cancer who failed prior therapies show very positive trends” News: https://bit.ly/3QyldE6 #BCTX #Biotech #ClinicalTrials

0 · Reply

focafoca99 Apr. 20 at 1:39 PM

$BCTX presented positive Phase 3 quality-of-life data and Phase 2 biomarker results at AACR 2026. https://www.rapidticker.com/news/bctx-briacell-presents-positive-phase-3-72cb52

0 · Reply

prismmarketview Apr. 20 at 1:09 PM

(NASDAQ: $BCTX) BriaCell Therapeutics has been added to the PRISM Emerging Biotech Index. The company is advancing Bria-IMT™, a cell-based immunotherapy in a pivotal Phase 3 study for metastatic breast cancer with FDA Fast Track designation. This week at AACR 2026, BriaCell is presenting four posters, including new Phase 3 data, additional Phase 2 analyses, and preclinical data supporting its next-gen Bria-OTS+™ platform. With multiple near-term catalysts and an “off-the-shelf” personalized immunotherapy approach, BCTX adds a high-conviction oncology name to the index. @BriaCell #BriaCellTherapeutics #MetastaticBreastCancer https://prismmarketview.com/companies/briacell-therapeutics-corp/

0 · Reply

SmallCapGrowth Apr. 20 at 12:58 PM

$BCTX: presented positive Phase 3 quality of life data and new Phase 2 biomarker findings - In heavily pretreated metastatic breast cancer patients, QOL remained largely preserved - biomarker analysis could help identify patients most likely to benefit. https://bit.ly/3QyldE6

0 · Reply

Market Cap	32.12M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	398,600
Avg Vol	199,652
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	3%
Beta	1.30
Analysts	Strong Buy
Price Target	$40.00